Targegen

Small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation.

placeSan Diego, California, United States calendar_todayFounded 2002 groups5 employees language targegen.com

Innovation

30 patent families (12 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace dormant. Cited 3,348 times.

YearFilings
201214
20136
20145
20153
20162
20172
20182
20192

Investor mix

10 investors on record; 2 have since exited.

Investor typeCountShare
Venture capital770%
Private equity110%
Other / undisclosed220%
Coming soon